|drug2805||Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki||0.45|
There is one clinical trial.
Since the outbreak of coronavirus disease - COVID-19 pandemic, most attention has focused on mode of transmission, clinical picture of the disease, treatment and prevention. In the coming weeks and months emphasis will gradually involve the post- acute care of COVID-19 survivors. It is anticipated that COVID-19 may have major impact on physical, cognitive, mental, social health status even in patients with mild disease. Moreover, pulmonary, radiologic, laboratory, sleep issues remain to be addressed
Description: scale 0-64 pointsMeasure: number of functional limitations post COVID-19 Time: 3-6 month
Description: Hamilton scale, pointsMeasure: number of psychologic changes Time: 3-6 months
Description: ESS scale 0-20, pointsMeasure: Sleep Disturbance and quality Time: 3-6 months
Description: Chest HRCTMeasure: Radiologic changes Time: 3-6 months
Description: Complete blood count, C - reactive protein, serum ferritinMeasure: Laboratory changes Time: 3-6 moths
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports